Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

  • In development
  • GID-TA11745
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Axatilimab within its marketing authorisation for treating graft versus host disease ID6570